SM08502 clinical trials
Also written Cirtuvivint.
How each study uses SM08502 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SM08502 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
National Cancer Institute (NCI) (1) · University of Colorado, Denver (1) · Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas (1) · Biosplice Therapeutics, Inc. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test SM08502.
- Apr 2027Cirtuvivint in Selected Advanced Soft-Tissue SarcomasPhase 2 · Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Studies
Open first, then newest update. How each study uses SM08502 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromesRecruitingPhase 1National Cancer Institute (NCI)NCT06484062Written as Cirtuvivint
- Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerRecruitingPhase 1University of Colorado, DenverNCT06856499Written as Cirtuvivint
- Cirtuvivint in Selected Advanced Soft-Tissue SarcomasRecruitingPhase 2Asociación Europea y Latinoamericana SELNET para la Investigación en SarcomasNCT07032285Written as Cirtuvivint
- A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid TumorsTerminatedPhase 1Biosplice Therapeutics, Inc.NCT03355066Written as SM08502
Given beside what is tested · 2 — SM08502 is usual care or a partner of the new treatment
- Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)RecruitingPhase 1/2Washington University School of MedicineNCT07155200Written as Cirtuvivint
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid TumorsTerminatedPhase 1Biosplice Therapeutics, Inc.NCT05084859Written as SM08502
Codes
What other systems call SM08502 · ClinicalTrials.gg INT015529
- UNII (FDA) 7T1PY32ZPHCIRTUVIVINTConfirmed FDA, Wikidata
- Wikidata Q124448796SM08502Confirmed FDA, Wikidata
- DrugBank DB17269One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7T1PY32ZPH | CIRTUVIVINT | Confirmed FDA, Wikidata |
| Wikidata | Q124448796 | SM08502 | Confirmed FDA, Wikidata |
| DrugBank | DB17269 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.